scPharmaceuticals (NASDAQ:SCPH) Announces Quarterly Earnings Results, Beats Estimates By $0.05 EPS

scPharmaceuticals (NASDAQ:SCPH) released its earnings results on Wednesday. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.05, Zacks reports. The firm had revenue of $12.15 million during the quarter, compared to analyst estimates of $12.08 million. scPharmaceuticals had a negative net margin of 264.60% and a negative return on equity of 244.93%.

scPharmaceuticals Price Performance

Shares of SCPH stock opened at $3.01 on Friday. scPharmaceuticals has a 12 month low of $2.75 and a 12 month high of $5.70. The company has a market capitalization of $150.62 million, a P/E ratio of -1.58 and a beta of 0.40. The stock has a 50 day moving average of $3.28 and a two-hundred day moving average of $3.80. The company has a current ratio of 8.08, a quick ratio of 6.89 and a debt-to-equity ratio of 1.66.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on SCPH. HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of scPharmaceuticals in a research note on Thursday. Maxim Group lowered their price objective on shares of scPharmaceuticals from $20.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.